As TIGIT optimism surges, commercial prospects become the question

A Phase III data leak from Roche’s tiragolumab program has re-ignited hope that the once written off TIGIT program may reach the market after all. The question now, assuming the data hold up in the final analysis, is whether excitement about the scientific victory is aligned with the product’s commercial prospects. 

On Wednesday, the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) acknowledged an inadvertent disclose of data from the second interim analysis of the Phase III SKYSCRAPER-01 study evaluating the checkpoint inhibitor combo of tiragolumab plus PD-L1 inhibitor Tecentriq atezolizumab as first-line therapy to treat locally advanced or metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression (TPS >50)...